RxDoctor Payments Data

Matthew Lobosco, MD

Psychiatry · Maplewood, NJNPI 1487896148

Payments from drug & device makers

$2,591in general payments, 2019–2025

Across 91 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$607
  • Otsuka America Pharmaceutical, Inc.$474
  • Lundbeck LLC$413
  • Alkermes, Inc.$179
  • AbbVie$142
  • Almatica Pharma LLC$137
  • plus $641 from 13 others

What the payments were for

  • Food & beverage$2,36891%
  • Education$2239%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,591 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$33,203
Medicare patients
147
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate24$81,080
Chlorpromazine Hcl66$21,671
Divalproex Sodium ErDivalproex Sodium129$9,381
Aripiprazole89$6,624
Paliperidone ErPaliperidone16$6,113
Fluphenazine Hcl19$5,002
Divalproex Sodium61$4,366
Clozapine41$4,102
Quetiapine Fumarate159$3,980
Clomipramine Hcl21$2,932
Olanzapine96$2,827
Oxcarbazepine39$2,690
Haloperidol63$2,235
Risperidone192$2,191
Ziprasidone Hcl22$2,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$57$81,08024 claims
Lilly USA, LLCOlanzapine$19$2,82796 claims
Almatica Pharma LLCSertraline Hcl$137$74562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Maplewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →